Cipla faces headwinds but remains resilient with strong product portfolio, robust earnings growth potential, and reasonable ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

Join us on the Cipla Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay in ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to market clobetasol ...

Formosa Pharmaceuticals and Cipla Limited have entered into an exclusive licensing agreement for the commercialization of ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...